文献速递肝病消化道肿瘤与早癌

HepatoScore-14:生物学异质性指标显著改善肝细胞癌风险预测

HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.
PubMed 文献 · Hepatology · 2021-06-15

研究前瞻性采集767例肝细胞癌患者和200例对照的血浆,量化317种蛋白,构建反映生物异常程度的HepatoScore及仅需14种蛋白的HepatoScore-14。患者按评分分为低、中、高三组,中位总生存分别为38.2、18.3、7.1个月(P < 0.0001),且HepatoScore能在现有分期系统内准确再分层。

要点

  • HepatoScore-14仅需14种代表性蛋白即可反映整体生物学效应。
  • 低、中、高评分组中位总生存分别为38.2、18.3、7.1个月(P < 0.0001)。
  • HepatoScore在几乎所有现有预后因素和分期系统内可准确再分层(P < 0.0001)。

核心结论

  • HepatoScore-14可增强现有肝细胞癌分期系统,显著改善患者预后评估、治疗决策和临床试验入组。

研究设计与样本

  • 前瞻性采集767例肝细胞癌患者和200例对照的血浆样本。
  • 在经临床实验室改进修正案认证的生物标志物检测实验室中定量317种蛋白。
  • 构建0到1的循环生物标志物异常评分HepatoScore,并构建仅需14种代表性蛋白的单样本评分HepatoScore-14。
  • 采用log-rank检验评估评分在现有分期系统/预后因素内的再分层能力。

主要发现

  • 患者按HepatoScore分为低、中、高三组,中位总生存分别为38.2、18.3、7.1个月(P < 0.0001)。
  • HepatoScore在现有预后因素和分期系统各水平内准确再分层(几乎所有比较P < 0.0001)。
  • HepatoScore-14在重复训练/测试拆分中严格验证,结果与HepatoScore一致。
  • HepatoScore-14在Myriad RBM(Austin, TX)和酶联免疫吸附试验试剂盒间结果一致,并被确立为独立预后因素。

临床怎么用

  • 作者认为HepatoScore-14可增强现有肝细胞癌分期系统,显著改善患者预后评估、治疗决策和临床试验入组。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Therapeutic, clinical trial entry and stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using clinical staging systems based on small numbers of empirically selected variables that insufficiently account for differences in biological characteristics of individual patients' disease. APPROACH AND RESULTS: We propose an approach for constructing risk scores from circulating biomarkers that produce a global biological characterization of individual patient's disease. Plasma samples were collected prospectively from 767 patients with HCC and 200 controls, and 317 proteins were quantified in a Clinical Laboratory Improvement Amendments-certified biomarker testing laboratory. We constructed a circulating biomarker aberration score for each patient, a score between 0 and 1 that measures the degree of aberration of his or her biomarker panel relative to normal, which we call HepatoScore. We used log-rank tests to assess its ability to substratify patients within existing staging systems/prognostic factors. To enhance clinical application, we constructed a single-sample score, HepatoScore-14, which requires only a subset of 14 representative proteins encompassing the global biological effects. Patients with HCC were split into three distinct groups (low, medium, and high HepatoScore) with vastly different prognoses (medial overall survival 38.2/18.3/7.1 months; P < 0.0001). Furthermore, HepatoScore accurately substratified patients within levels of existing prognostic factors and staging systems (P < 0.0001 for nearly all), providing substantial and sometimes dramatic refinement of expected patient outcomes with strong therapeutic implications. These results were recapitulated by HepatoScore-14, rigorously validated in repeated training/test splits, concordant across Myriad RBM (Austin, TX) and enzyme-linked immunosorbent assay kits, and established as an independent prognostic factor. CONCLUSIONS: HepatoScore-14 augments existing HCC staging systems, dramatically refining patient prognostic assessments and therapeutic decision making and enrollment in clinical trials. The underlying strategy provides a global biological characterization of disease, and can be applied broadly to other disease settings and biological media.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Morris JS, Hassan MM, Zohner YE, et al. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021. PMID: 32931023. doi:10.1002/hep.31555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。